Faculty profile

Jean-Jacques Lebrun

ResearcherMedicineMcGill University

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a McGill University directory, so their courses may be missing. Find their university profile.

Jean-Jacques Lebrun

Researcher

Medicine

Health Sciences

McGill University

Montreal, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
14 publications in the last five years, latest in 2026.
Senior (last) author on 11 recent papers, a sign of leading a research group.
Principal investigator on 9 research grants (9 CIHR), most recently in 2025.
Supervised 2 trainees who won CIHR awards, most recently in 2012.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Triple Negative Breast Cancer Preclinical Models Of Breast Cancer Cdk4/6 Kinase Inhibitors Combination Therapy Crispr Genome-Wide Screen Customized "Druggable Target" Crispr Library Dna Repair Nhej Inhibitors

Latest papers

In vivo CRISPR screening identifies metastasis suppressors in triple-negative breast cancer.
Nature communications · 2026 · senior author
Molecular insights into the PRLR-Hippo-YAP axis in breast cancer therapeutics.
Expert opinion on therapeutic targets · 2026 · senior author
Identification of HSPE1 as a new actionable cancer vulnerability leads to an innovative and effective combination therapy for pancreatic ductal adenocarcinoma.
Molecular cancer · 2026 · senior author

All 54 publications

Latest funding

Crisperized Medicine for Therapeutic Profiling and Drug Repositioning
CIHR · 2025 · Nominated PI
$1,193,400
Engineering metabolically stable molecules toward tandem targeting of EGFR, its variant EGFRvIII and DNA for killing stem cells and preventing recurrence in the treatment of glioblastom multiforme (GBM)
CIHR · 2024 · Co-investigator
$956,250
Exploiting a novel dual-specificity cell cycle inhibitor, KP108 as a therapeutic approach for metastatic breast cancer
CIHR · 2022 · Nominated PI
$1,220,175

All 15 grants and awards

54 publications.

In vivo CRISPR screening identifies metastasis suppressors in triple-negative breast cancer.

Galal S, Chaltel Lima L, Wang N, Moury C, Yan G, Dai M, Ali S, Lebrun JJ

Nature communications2026Senior author

DOI: 10.1038/s41467-026-76293-x PMID: 42680732

Molecular insights into the PRLR-Hippo-YAP axis in breast cancer therapeutics.

Ali S, Lebrun JJ

Expert opinion on therapeutic targets2026Senior author

DOI: 10.1080/14728222.2026.2671687 PMID: 42096243

Identification of HSPE1 as a new actionable cancer vulnerability leads to an innovative and effective combination therapy for pancreatic ductal adenocarcinoma.

Boudreault J, Rahimirad S, Wang N, Yan G, Lima LC, Poulet S, Dai M, Ali S, Lebrun JJ

Molecular cancer2026Senior author

DOI: 10.1186/s12943-026-02587-9 PMID: 41645202

A novel clinically relevant antagonistic interplay between prolactin and oncogenic YAP-CCN2 pathways as a differentiation therapeutic target in breast cancer.

Liu X, Moamer A, Gomes da Silva R, Shoham-Amizlev A, Hamam D, Shams A, Lebrun JJ, Ali S

Cell death & disease2025

DOI: 10.1038/s41419-025-07547-7 PMID: 40157909

Author Correction: Targeting the DYRK1A kinase prevents cancer progression and metastasis and promotes cancer cells response to G1/S targeting chemotherapy drugs.

Laham AJ, El-Awady R, Saber-Ayad M, Wang N, Yan G, Boudreault J, Ali S, Lebrun JJ

NPJ precision oncology2024Senior author

DOI: 10.1038/s41698-024-00628-4 PMID: 38977910

Targeting the DYRK1A kinase prevents cancer progression and metastasis and promotes cancer cells response to G1/S targeting chemotherapy drugs.

Laham AJ, El-Awady R, Saber-Ayad M, Wang N, Yan G, Boudreault J, Ali S, Lebrun JJ

NPJ precision oncology2024Senior author

DOI: 10.1038/s41698-024-00614-w PMID: 38839871

Multiple Endocrine Neoplasia Type 1 Regulates TGFβ-Mediated Suppression of Tumor Formation and Metastasis in Melanoma.

Boudreault J, Canaff L, Ghozlan M, Wang N, Guarnieri V, Salcuni AS, Scillitani A, Goltzman D, Ali S, Lebrun JJ

Cells2024Senior author

DOI: 10.3390/cells13110973 PMID: 38891107

Genome-wide in vivo CRISPR screen identifies TGFβ3 as actionable biomarker of palbociclib resistance in triple negative breast cancer.

Poulet S, Dai M, Wang N, Yan G, Boudreault J, Daliah G, Guillevin A, Nguyen H, Galal S, Ali S, Lebrun JJ

Molecular cancer2024Senior author

DOI: 10.1186/s12943-024-02029-4 PMID: 38831405

Transforming Growth Factor-β/Smad Signaling Inhibits Melanoma Cancer Stem Cell Self-Renewal, Tumor Formation and Metastasis.

Boudreault J, Wang N, Ghozlan M, Lebrun JJ

Cancers2024Senior author

DOI: 10.3390/cancers16010224 PMID: 38201651

Combined in vitro/in vivo genome-wide CRISPR screens in triple negative breast cancer identify cancer stemness regulators in paclitaxel resistance.

Yan G, Dai M, Poulet S, Wang N, Boudreault J, Daliah G, Ali S, Lebrun JJ

Oncogenesis2023Senior author

DOI: 10.1038/s41389-023-00497-9 PMID: 37932309

Something wrong or missing on this profile? Suggest a correction

Jean-Jacques Lebrun

Research

Latest papers

Latest funding

In vivo CRISPR screening identifies metastasis suppressors in triple-negative breast cancer.

Molecular insights into the PRLR-Hippo-YAP axis in breast cancer therapeutics.

Identification of HSPE1 as a new actionable cancer vulnerability leads to an innovative and effective combination therapy for pancreatic ductal adenocarcinoma.

A novel clinically relevant antagonistic interplay between prolactin and oncogenic YAP-CCN2 pathways as a differentiation therapeutic target in breast cancer.

Author Correction: Targeting the DYRK1A kinase prevents cancer progression and metastasis and promotes cancer cells response to G1/S targeting chemotherapy drugs.

Targeting the DYRK1A kinase prevents cancer progression and metastasis and promotes cancer cells response to G1/S targeting chemotherapy drugs.

Multiple Endocrine Neoplasia Type 1 Regulates TGF&#x3b2;-Mediated Suppression of Tumor Formation and Metastasis in Melanoma.

Genome-wide in vivo CRISPR screen identifies TGF&#x3b2;3 as actionable biomarker of palbociclib resistance in triple negative breast cancer.

Transforming Growth Factor-&#x3b2;/Smad Signaling Inhibits Melanoma Cancer Stem Cell Self-Renewal, Tumor Formation and Metastasis.

Combined in vitro/in vivo genome-wide CRISPR screens in triple negative breast cancer identify cancer stemness regulators in paclitaxel resistance.

Frequent collaborators

Suhad Ali

Xi-Long Zheng

Christos Boutopoulos

Shashi Gujar

Morag Park

Yasir Mohamud

Thomas Pulinilkunnil

David Goltzman

Ina Dobrinski

Michael Sacher

Martin Post

Sabah Hussain

Robert Sladek

Caigan Du

Honglin Luo

Sandra Turcotte

Michel Meunier

Przemyslaw Sapieha

Bertrand Jean-Claude

Gary Sweeney

Isabella Caniggia

Przemyslaw Sapieha

Nigil Haroon

Morag Park

Steve Jean

Xiang-Jiao Yang

Khosrow Adeli

Sophie Roux

Multiple Endocrine Neoplasia Type 1 Regulates TGFβ-Mediated Suppression of Tumor Formation and Metastasis in Melanoma.

Genome-wide in vivo CRISPR screen identifies TGFβ3 as actionable biomarker of palbociclib resistance in triple negative breast cancer.

Transforming Growth Factor-β/Smad Signaling Inhibits Melanoma Cancer Stem Cell Self-Renewal, Tumor Formation and Metastasis.